Vanguard Group
CSTL icon

Vanguard Group’s Castle Biosciences CSTL Stock Holding History

Vanguard Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$85.6M Buy
2,199,829
+27,511
+1% +$887K ﹤0.01% 1935
2025
Q3 		$49.5M Buy
2,172,318
+2,290
+0.1% +$46.5K ﹤0.01% 2158
2025
Q2 		$44.3M Buy
2,170,028
+122,463
+6% +$2.27M ﹤0.01% 2180
2025
Q1 		$41M Buy
2,047,565
+215,030
+12% +$5.32M ﹤0.01% 2174
2024
Q4 		$48.8M Buy
1,832,535
+83,783
+5% +$2.55M ﹤0.01% 2167
2024
Q3 		$49.9M Buy
1,748,752
+171,238
+11% +$4.36M ﹤0.01% 2180
2024
Q2 		$34.3M Buy
1,577,514
+83,338
+6% +$1.86M ﹤0.01% 2300
2024
Q1 		$33.1M Buy
1,494,176
+32,695
+2% +$711K ﹤0.01% 2354
2023
Q4 		$31.5M Buy
1,461,481
+22,093
+2% +$389K ﹤0.01% 2383
2023
Q3 		$24.3M Buy
1,439,388
+11,967
+0.8% +$209K ﹤0.01% 2471
2023
Q2 		$19.6M Buy
1,427,421
+23,520
+2% +$477K ﹤0.01% 2597
2023
Q1 		$31.9M Buy
1,403,901
+11,177
+0.8% +$273K ﹤0.01% 2389
2022
Q4 		$32.8M Buy
1,392,724
+141,991
+11% +$3.29M ﹤0.01% 2380
2022
Q3 		$32.6M Buy
1,250,733
+39,937
+3% +$1.12M ﹤0.01% 2396
2022
Q2 		$26.6M Buy
1,210,796
+34,569
+3% +$803K ﹤0.01% 2508
2022
Q1 		$52.8M Buy
1,176,227
+13,386
+1% +$553K ﹤0.01% 2279
2021
Q4 		$49.9M Sell
1,162,841
-3,347
-0.3% -$175K ﹤0.01% 2355
2021
Q3 		$77.6M Buy
1,166,188
+38,996
+3% +$2.74M ﹤0.01% 2127
2021
Q2 		$82.7M Buy
1,127,192
+112,070
+11% +$7.4M ﹤0.01% 2102
2021
Q1 		$69.5M Buy
1,015,122
+84,597
+9% +$6.36M ﹤0.01% 2133
2020
Q4 		$62.5M Buy
930,525
+276,466
+42% +$15M ﹤0.01% 2082
2020
Q3 		$33.7M Buy
654,059
+112,310
+21% +$5M ﹤0.01% 2220
2020
Q2 		$20.4M Buy
541,749
+322,259
+147% +$11M ﹤0.01% 2417
2020
Q1 		$6.54M Buy
219,490
+18,988
+9% +$573K ﹤0.01% 2827
2019
Q4 		$6.89M Buy
200,502
+87,589
+78% +$2.14M ﹤0.01% 3041
2019
Q3 		$2.04M Buy
+112,913
New +$2.5M ﹤0.01% 3444

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Vanguard Group's CSTL Position: Q4 2025 in Review

Vanguard Group increased its Castle Biosciences (CSTL) stake by 1.3% in Q4 2025, buying an estimated $887K and bringing the position to 2,199,829 shares worth $85.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1935.

Vanguard Group first reported a position in CSTL in Q3 2019 and has held it in 26 quarters since. 194 funds tracked by Wall St. Rank hold CSTL as of Q4 2025.

  • Vanguard Group held 2,199,829 shares of Castle Biosciences worth $85.6M as of Q4 2025.
  • Vanguard Group bought 27,511 Castle Biosciences shares in Q4 2025, an estimated $887K.
  • Castle Biosciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1935 holding.
  • Vanguard Group first reported a position in Castle Biosciences in Q3 2019 and has held it in 26 quarters since.
  • 194 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.